Conversely, YBX1 is recognized for its transcriptional control over HR repair genes and ABC transporters in cancer,[18, 19] leading us to posit that YBX1, rather than IGF2BP1, is the critical substrate through which PRMT3 regulates chemoradiotherapy resistance in rectal cancer. The gene discussed is PRMT3; the disease is rectal cancer.